Maximizing secondary prevention for patients with ASCVD: Where does colchicine fit in cardiovascular disease prevention?

Benjamin EJ Munterner P Alonso A , et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation 2019;139:e56-e528.

Alnasser SM Huang W Gore J , et al. Late consequences of acute coronary syndromes: Global Registry of Acute Coronary Events (GRACE) follow up. Am J Med 2015;128(7):766-75.

Levine GN Bates ER Bittl JA , et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 2016;68(10):1082-115.

Ibanez B James S Agewall S , et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39(2):119-77.

Fitchett D Leiter L Lin P , et al. Update to evidence-based secondary prevention strategies after acute coronary syndrome. CJC Open 2020;2(5):402-15.

Mehta S Bainey K Cantor W , et al. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy. Can J Cardiol 2018;34(3):214-33.

Pearson G Thanassoulis G Anderson T , et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol 2021;37(8):1129-50.

2020-2022 Hypertension Highlights. Hypertension Canada. Guidelines—hypertension Canada. Available: https://guidelines.hypertension.ca/prevention-treatment/hypertension-with-ischemic-heart-disease (accessed Mar. 15, 2023).

Diabetes Canada. Diabetes Canada clinical practice guidelines. Available: guidelines.diabetes.ca/2020-Update; https://guidelines.diabetes.ca/docs/resources/prescription-for-cardiovascular-pretection-with-diabetes.pdf (accessed Mar. 15, 2023).

Ridker PM Everett BM Thuren T , et al. Anti-inflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377(12):1119-31.

Lawler P Bhatt D Godoy L , et al. Targeting cardiovascular inflammation: next steps in clinical translation. E Heart J 2021;42(1):113-31.

Badimon L Vilahur G . Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med 2014;276(6):618-32.

Ridker PM Everett BM Pradhan A , et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019;380(8):752-62.

Nidorf SM Eikelboom JW Budgeon CA Thompson PL . Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013;61(4):404-10.

Nidorf SM Fiolet A Mostad A . et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020;383(19):1838-47.

Tardif JC Kouz S Waters D , et al. Efficacy and safety of low dose colchicine after myocardial infarction. N Engl J Med 2019;381(26):2497-505.

Samuel M Tardif JC Bouabdallaoui N , et al. Colchicine for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. Can J Cardiol 2021;37(5):776-85.

Kofler T Kurmann R Lehnick D , et al. Colchicine in patients with coronary artery disease: a systematic review and meta-analysis of randomized trials. J Am Heart Assoc 2021;10(16):e021198.